Drugs / CD33*CD3 BsAb
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05077423 | May → Dec 2022 | childhood acute myeloid leukemia | Y-mAbs Therapeutics | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD33*CD3 BsAb | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05077423 ↗ |
| Modality | Monoclonal antibody | “CD33xCD3 is a bispecific monoclonal antibody” NCT05077423 ↗ |
| Route | Subcutaneous | “administered subcutaneously” NCT05077423 ↗ |
| Target | CD33 | “specifically targets CD33 on the AML blasts and CD3 on the T cells” NCT05077423 ↗ |